Tyra Biosciences, Inc. $TYRA Holdings Increased by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in Tyra Biosciences by 23.6%, owning 301,801 shares valued at approximately $2.8 million as of the latest SEC filing.
• A significant number of institutional investors have also boosted their holdings in Tyra Biosciences, with 84.14% of shares owned by institutions as of the last quarter.
• Recent stock analyst reports show a favorable outlook for Tyra Biosciences, with price targets as high as $35.00 and a consensus rating of "Buy."

Jacobs Levy Equity Management Inc. grew its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 23.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 301,801 shares of the company's stock after purchasing an additional 57,556 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.57% of Tyra Biosciences worth $2,807,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at approximately $60,000. Two Sigma Advisers LP acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at approximately $171,000. Deutsche Bank AG boosted its position in Tyra Biosciences by 52.0% during the fourth quarter. Deutsche Bank AG now owns 18,909 shares of the company's stock worth $263,000 after acquiring an additional 6,466 shares during the last quarter. Bank of America Corp DE boosted its position in Tyra Biosciences by 21.7% during the fourth quarter. Bank of America Corp DE now owns 66,157 shares of the company's stock worth $920,000 after acquiring an additional 11,804 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in Tyra Biosciences by 42.7% during the first quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock worth $110,000 after acquiring an additional 3,550 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Stock Down 1.9%

Shares of TYRA traded down $0.24 during midday trading on Monday, hitting $12.29. The company had a trading volume of 9,983 shares, compared to its average volume of 296,189. The company's 50 day moving average price is $11.19 and its 200 day moving average price is $10.25. The stock has a market cap of $654.79 million, a price-to-earnings ratio of -6.79 and a beta of 1.09. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.06. Equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, August 22nd. Oppenheimer reissued an "outperform" rating and issued a $36.00 target price on shares of Tyra Biosciences in a research report on Wednesday. Piper Sandler began coverage on shares of Tyra Biosciences in a research report on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 target price on the stock. Wall Street Zen upgraded shares of Tyra Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Raymond James Financial began coverage on shares of Tyra Biosciences in a report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $35.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $31.86.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Gilla Kaplan sold 9,568 shares of the business's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total transaction of $93,575.04. Following the completion of the transaction, the director directly owned 28,231 shares of the company's stock, valued at $276,099.18. The trade was a 25.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.20% of the stock is owned by insiders.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.